SCHEDULE 13G: Janus Henderson Group Discloses 5.6% Passive Stake in Entrada Therapeutics

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed beneficial ownership of 5.6% of Entrada Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Janus Henderson Group PLC, a Jersey-based entity, reported beneficial ownership of 2,080,367 shares of Entrada Therapeutics, Inc. common stock, representing 5.6% of the class.
• Janus Henderson Biotech Innovation Master Fund Ltd, a Massachusetts-based investment company and an affiliate of Janus Henderson Group PLC, reported beneficial ownership of 1,884,826 shares, representing 5.0% of the class.
• Both reporting entities hold shared voting and shared dispositive power over their respective reported shares.
• The shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing the control of Entrada Therapeutics, Inc.
• The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating a passive investment intent.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of beneficial ownership by an institutional investor, indicating a passive stake without intent to influence control.

Risks

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of a significant passive investment by a major asset manager in a biotechnology company. It reflects an investment decision by Janus Henderson Group and its biotech-focused fund, indicating their position in Entrada Therapeutics within their managed portfolios.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially signaling confidence from a major investment group.

Key Dates

Keywords

Entrada Therapeutics, Janus Henderson Group, Janus Henderson Biotech Innovation Master Fund, SEC filing, Schedule 13G, beneficial ownership, common stock, investment adviser, biotech, passive investment